Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #221465 on Biotech Values
DewDiligence
10/18/18 2:33 PM
#221479 RE: puravida #221465
03/23/21 12:19 PM
#237515 RE: puravida #221465
Novartis today reported the first interpretable results of the Phase III VISION study evaluating the efficacy and safety of 177Lu-PSMA-617, a targeted radioligand therapy in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) compared to best standard of care alone. The trial met both primary endpoints of overall survival and radiographic progression-free survival…